SrasV1, PubMed, Checkpoint, bibRecord, 002D64

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.

Identifieur interne : 002D64 ( PubMed/Checkpoint ); précédent : 002D63; suivant : 002D65

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.

Auteurs : Yunshan Wang [République populaire de Chine] ; Shanhui Sun ; Hong Shen ; Lihua Jiang ; Maoxiu Zhang ; Dongjie Xiao ; Yang Liu ; Xiaoli Ma ; Yong Zhang ; Nongjian Guo ; Tanghong Jia

Source :

Cellular & molecular immunology [ 1672-7681 ] ; 2004.

RBID : pubmed:16225774

Descripteurs français

KwdFr :
- Animaux, Antigènes viraux (immunologie), Autoanticorps (immunologie), Autoanticorps (sang), Faux positifs, Humains, Lignée cellulaire, Maladies auto-immunes (immunologie), Maladies auto-immunes (sang), Réactions croisées, Spécificité des anticorps, Test ELISA, Tests sérologiques, Virus du SRAS (immunologie).
MESH :
- immunologie : Antigènes viraux, Autoanticorps, Maladies auto-immunes, Virus du SRAS.
- sang : Autoanticorps, Maladies auto-immunes.
- Animaux, Faux positifs, Humains, Lignée cellulaire, Réactions croisées, Spécificité des anticorps, Test ELISA, Tests sérologiques.

English descriptors

KwdEn :
- Animals, Antibody Specificity, Antigens, Viral (immunology), Autoantibodies (blood), Autoantibodies (immunology), Autoimmune Diseases (blood), Autoimmune Diseases (immunology), Cell Line, Cross Reactions, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Humans, SARS Virus (immunology), Serologic Tests.
MESH :
- chemical , blood : Autoantibodies.
- chemical , immunology : Antigens, Viral, Autoantibodies.
- blood : Autoimmune Diseases.
- immunology : Autoimmune Diseases, SARS Virus.
- Animals, Antibody Specificity, Cell Line, Cross Reactions, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Humans, Serologic Tests.

Abstract

To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.

PubMed: 16225774

Affiliations:

République populaire de Chine

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002500
to stream PubMed, to step Curation: 002500

Links to Exploration step

pubmed:16225774

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</title>
<author><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan</wicri:regionArea>
<wicri:noRegion>Jinan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
</author>
<author><name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
</author>
<author><name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
</author>
<author><name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
</author>
<author><name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
</author>
<author><name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
</author>
<author><name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
</author>
<author><name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</author>
<author><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
</author>
<author><name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:16225774</idno>
<idno type="pmid">16225774</idno>
<idno type="wicri:Area/PubMed/Corpus">002500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002500</idno>
<idno type="wicri:Area/PubMed/Curation">002500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002500</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D64</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002D64</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</title>
<author><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan</wicri:regionArea>
<wicri:noRegion>Jinan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
</author>
<author><name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
</author>
<author><name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
</author>
<author><name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
</author>
<author><name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
</author>
<author><name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
</author>
<author><name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
</author>
<author><name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</author>
<author><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
</author>
<author><name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
</author>
</analytic>
<series><title level="j">Cellular & molecular immunology</title>
<idno type="ISSN">1672-7681</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Antigens, Viral (immunology)</term>
<term>Autoantibodies (blood)</term>
<term>Autoantibodies (immunology)</term>
<term>Autoimmune Diseases (blood)</term>
<term>Autoimmune Diseases (immunology)</term>
<term>Cell Line</term>
<term>Cross Reactions</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>False Positive Reactions</term>
<term>Humans</term>
<term>SARS Virus (immunology)</term>
<term>Serologic Tests</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antigènes viraux (immunologie)</term>
<term>Autoanticorps (immunologie)</term>
<term>Autoanticorps (sang)</term>
<term>Faux positifs</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Maladies auto-immunes (immunologie)</term>
<term>Maladies auto-immunes (sang)</term>
<term>Réactions croisées</term>
<term>Spécificité des anticorps</term>
<term>Test ELISA</term>
<term>Tests sérologiques</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Autoimmune Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Autoanticorps</term>
<term>Maladies auto-immunes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Autoimmune Diseases</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Autoanticorps</term>
<term>Maladies auto-immunes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Cell Line</term>
<term>Cross Reactions</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>False Positive Reactions</term>
<term>Humans</term>
<term>Serologic Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Faux positifs</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Réactions croisées</term>
<term>Spécificité des anticorps</term>
<term>Test ELISA</term>
<term>Tests sérologiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16225774</PMID>
<DateCompleted><Year>2006</Year>
<Month>02</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2005</Year>
<Month>10</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7681</ISSN>
<JournalIssue CitedMedium="Print"><Volume>1</Volume>
<Issue>4</Issue>
<PubDate><Year>2004</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Cellular & molecular immunology</Title>
<ISOAbbreviation>Cell. Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</ArticleTitle>
<Pagination><MedlinePgn>304-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yunshan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>Shanhui</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Lihua</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Maoxiu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xiao</LastName>
<ForeName>Dongjie</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Xiaoli</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guo</LastName>
<ForeName>Nongjian</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jia</LastName>
<ForeName>Tanghong</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Cell Mol Immunol</MedlineTA>
<NlmUniqueID>101242872</NlmUniqueID>
<ISSNLinking>1672-7681</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16225774</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
<name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
<name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
<name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
<name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
<name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
<name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
<name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
<name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
<name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D64 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002D64 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:16225774
   |texte=   Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:16225774" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.

Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki